期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 482, 期 3, 页码 459-469出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2016.10.100
关键词
BCL-2; Apoptosis; Cancer; BH3-Mimetics; ABT-199; Venetoclax
资金
- Leukemia Foundation of Australia
- National Health and Medical Research Council [1020363, 1016701, 10460101, 1059290, 1078924]
- Cancer Council Victoria [1052309]
- Leukemia and Lymphoma Society [7001-13]
- Australian Government IRISS
- Victorian State Government [OIS 9000220]
- National Health and Medical Research Council of Australia [1078924, 1059290] Funding Source: NHMRC
In 1988, the BCL-2 protein was found to promote cancer by limiting cell death rather than enhancing proliferation. This discovery set the wheels in motion for an almost 30 year journey involving many international research teams that has recently culminated in the approval for a drug, ABT-199/venetoclax/Venclexta that targets this protein in the treatment of cancer. This review will describe the long and winding path from the discovery of this protein and understanding the fundamental process of apoptosis that BCL-2 and its numerous homologues control, through to its exploitation as a drug target that is set to have significant benefit for cancer patients. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据